Sandu Pharmaceuticals Ltd
₹35.74▲ +0.08 (+0.22%)
SANDUPHQ·BSE·Healthcare
Market Cap
33.94 Cr
PE Ratio
19.53
Volume
97
Day High - Low
36.39 - 33.55
52W High-Low
50.00 - 30.00
₹35.74▲ +0.08 (+0.22%)
Market Cap33.94 Cr
PE Ratio19.53
Volume97
Day High - Low36.39 - 33.55
52W High-Low50.00 - 30.00
Sandu Pharmaceuticals Ltd (SANDUPHQ): company summary
The company's annual revenue rose 4.1% to ₹70 crore, while annual net profit remained flat at ₹2 crore.
Sandu Pharmaceuticals Ltd (SANDUPHQ) is a micro-cap Healthcare company valued at ₹34 crore operating in Pharmaceuticals on the NSE and BSE.
- Recent price move
- Sandu Pharmaceuticals Ltd last traded at ₹35.74, modestly up 0.22% on the day.
- Recent developments
- On 2026-06-30, the company reported its latest quarter results, showing revenue of ₹16 crore and net profit of ₹0 crore. The company's promoter holding remained at 37.79% as of 2026-06-30, with no changes in foreign or domestic institutional holdings.
- Financial performance
- The company's annual revenue rose 4.1% to ₹70 crore, while annual net profit remained flat at ₹2 crore. The latest quarter saw revenue fall 1.9% year-on-year to ₹16 crore, with net profit unchanged at ₹0 crore compared to ₹0 crore a year earlier. The net profit margin improved by 0.2 percentage points to 2.5%, but return on equity and return on capital employed remained low at 4.0% and 6.3%, respectively.
- Valuation multiples
- The stock trades at 19.5 times earnings, a discount to the Healthcare median of 32.0, 1.04 times book value. It yields 2.6%.
- Things to watch
- The company's latest quarter net profit remained at ₹0 crore, despite a 4.5% change from the previous year. The stock is 28.7% below its 52-week high, and the company's return on equity and return on capital employed are low, indicating weak profitability. The company's revenue growth has been modest, with a 2.3% CAGR over the past three years.
- Where it stands
- The company's latest quarter net profit remained at ₹0 crore, with revenue falling 1.9% year-on-year. The stock is 28.7% below its 52-week high, and the company's return on equity and return on capital employed are low. The company's annual net profit remained flat at ₹2 crore, with a 14.2% increase from the previous year.
Summarised by DocStoX's model on 2026-10-18 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.
DocStoX Score
4.7/10
Weak
Fair Value
Sign in to see
ROE
4.04%
Weak
P/E
19.53x
Fair
Debt / Equity
0.01
Low
Industry
Healthcare
Pharmaceuticals
Overall View
Mixed
Price performance
Day₹33.55
₹36.39
52W₹30.00
₹50.00
DocStoX take
Supported by risk (7.6), but held back by momentum (2.0). Risk looks strong at 7.6, but that is offset by momentum at 2.0. We are calling it Mixed rather than resolving the conflict for you.
DocStoX score
Low confidence4.7
/10
Weak
Quality
Modest
ROE 4.0%
Valuation
Fair
P/E 19.5×
Growth
Slow
Revenue +3.5% 5Y CAGR
Risk
Low risk
D/E 0.01
Momentum
Weak
29% of 52-week range
At a glance
Market Cap
₹34 Cr
52W High / Low
₹50 / ₹30
Dividend Yield
2.64%
Promoter Holding
37.79%
EPS (TTM)
₹1.83
Book Value
₹45.21
Key highlights
- Low leverage — D/E 0.01
- Profitable in all of the last 5 years
- Momentum is weak (2.0/10)
- Revenue barely growing (4% a year)
2 Positives3 Watchouts
Growth
Financials
Technicals
Peers
News
Forecasts
About the company
More data
Filings, corporate actions and ownership detail — opened on demand.
More Healthcare stocks · Pharmaceuticals
Explore Sandu Pharmaceuticals Ltd’s valuation
Free deep-dive tools · no sign-up
Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.
Sandu Pharmaceuticals Ltd peers in Healthcare
Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.
Sun Pharmaceutical Industries LimitedDivi's Laboratories LimitedTorrent Pharmaceuticals LimitedLaurus Labs LimitedZydus Lifesciences LimitedApollo Hospitals Enterprise LimitedCipla LimitedDr. Reddy's Laboratories LimitedMankind Pharma LimitedAurobindo Pharma LimitedLupin LimitedManipal Health Enterprises Limited
Compare Sandu Pharmaceuticals Ltd with peers
Sandu Pharmaceuticals Ltd vs Sun Pharmaceutical Industries LimitedSandu Pharmaceuticals Ltd vs Divi's Laboratories LimitedSandu Pharmaceuticals Ltd vs Torrent Pharmaceuticals LimitedSandu Pharmaceuticals Ltd vs Laurus Labs LimitedSandu Pharmaceuticals Ltd vs Zydus Lifesciences LimitedSandu Pharmaceuticals Ltd vs Apollo Hospitals Enterprise Limited
Related tools & concepts
Value Sandu Pharmaceuticals Ltd with the ratios and calculators DocStoX uses in its analysis.
P/E RatioPrice to earningsReturn on Equity (ROE)ProfitabilityROCECapital efficiencyDebt to EquityLeverageP/B RatioPrice to bookNet Profit MarginBottom-line efficiencyDCF / Intrinsic ValueEstimate fair valueCAGR CalculatorAnnualised returnDividend YieldIncome on pricePosition SizeRisk-based sizingBrokerage CalculatorCharges on a tradeSIP CalculatorSystematic investing